TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07540832: A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC

Sponsor: Zhejiang Haichang Biotech Co., Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07540832 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07540832 Rescue Dossier →